UNSPSC 51241550: Polyvinyl alcohol/povidone/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.

UNSPSC 51241550 Polyvinyl alcohol/povidone/sodium chloride is a Commodity code used by state and local health systems to procure generic pharmaceuticals and over-the-counter products. State and local governments buy specific active pharmaceutical ingredients and finished OTC formulations under this code through cooperative purchasing vehicles that leverage volume across multiple jurisdictions to negotiate competitive pricing and ensure consistent supply to clinics, hospitals, emergency services, and institutional care facilities. Issuing bodies include state departments of health and administration, multistate cooperative purchasing alliances, and participating local health authorities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout repeat buyer using cooperative contracting to serve multiple states including Oregon.

The code sees active procurement across the upper Midwest and Pacific Northwest. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (Solicitation S1070000015802, posted January 20, 2026, due March 26, 2026) exemplifies current buying under this code: the alliance is establishing multiple contracts with manufacturers and seeking detailed product information keyed to National Drug Codes, with awarded vendors required to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC). Products must be available in the marketplace by May 15, 2026, with contract terms effective July 1, 2026. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers, and carry insurance including $5,000,000 commercial general liability per occurrence. The evaluation weights price competitiveness at 75 percent, with the remaining 25 percent split across fixed pricing, administrative-fee compliance, EDI capability, and pricing-structure flexibility (flat price, net price formats, or WAC-minus models).